NO20062792L - Farmasoytiske formuleringer omfattende metformin og et fibrat og fremgangsmater for oppnaelse derav - Google Patents

Farmasoytiske formuleringer omfattende metformin og et fibrat og fremgangsmater for oppnaelse derav

Info

Publication number
NO20062792L
NO20062792L NO20062792A NO20062792A NO20062792L NO 20062792 L NO20062792 L NO 20062792L NO 20062792 A NO20062792 A NO 20062792A NO 20062792 A NO20062792 A NO 20062792A NO 20062792 L NO20062792 L NO 20062792L
Authority
NO
Norway
Prior art keywords
fibrate
metformin
preparation
methods
pharmaceutical formulations
Prior art date
Application number
NO20062792A
Other languages
English (en)
Inventor
Leonard Mccarthy
Gordon Dawson
Original Assignee
Fournier Lab Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fournier Lab Ireland Ltd filed Critical Fournier Lab Ireland Ltd
Publication of NO20062792L publication Critical patent/NO20062792L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse angår granulater omfattende partikler av metformin og partikler av et fibrat. Oppfinnelsen angår videre farmasøytiske blandinger inneholdende slike granulater. Oppfinnelsen angår også fremgangsmåter for fremstilling av nevnte granulater og nevnte farmasøytiske blandinger.
NO20062792A 2004-01-23 2006-06-15 Farmasoytiske formuleringer omfattende metformin og et fibrat og fremgangsmater for oppnaelse derav NO20062792L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04001499A EP1559419A1 (en) 2004-01-23 2004-01-23 Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
PCT/EP2005/001524 WO2005070396A1 (en) 2004-01-23 2005-01-24 Pharmaceutical formulations comprising metformin and a fibrate, and processes for obtaining them

Publications (1)

Publication Number Publication Date
NO20062792L true NO20062792L (no) 2006-09-25

Family

ID=34639372

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062792A NO20062792L (no) 2004-01-23 2006-06-15 Farmasoytiske formuleringer omfattende metformin og et fibrat og fremgangsmater for oppnaelse derav

Country Status (21)

Country Link
US (2) US20080020046A1 (no)
EP (2) EP1559419A1 (no)
JP (1) JP4740881B2 (no)
CN (1) CN100531722C (no)
AT (1) ATE521338T1 (no)
AU (1) AU2005205930B2 (no)
BR (1) BRPI0507022A (no)
CA (1) CA2553967A1 (no)
CY (1) CY1111961T1 (no)
DK (1) DK1706102T3 (no)
EA (1) EA009773B1 (no)
ES (1) ES2370948T3 (no)
IL (1) IL176903A0 (no)
MA (1) MA28353A1 (no)
NO (1) NO20062792L (no)
PL (1) PL1706102T3 (no)
PT (1) PT1706102E (no)
SI (1) SI1706102T1 (no)
TN (1) TNSN06222A1 (no)
WO (1) WO2005070396A1 (no)
ZA (1) ZA200605882B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600371A (es) * 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
WO2007143099A2 (en) * 2006-06-01 2007-12-13 Sobel Burton E Methods for inhibiting cardiac pai-1
CA2672686A1 (en) * 2006-10-12 2008-04-17 Abbott Laboratories Pharmaceutical formulations
CA2638240C (en) * 2008-08-29 2010-02-02 Alexander Macgregor Method of treating dysglycemia and glucose excursions
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
WO2011154013A1 (en) * 2010-06-10 2011-12-15 Lifecycle Pharma A/S Pharmaceutical composition comprising fenofibric acid
ES2886022T3 (es) * 2010-09-21 2021-12-16 Intekrin Therapeutics Inc Composiciones farmacéuticas sólidas antidiabéticas
WO2013064853A1 (en) * 2011-11-05 2013-05-10 Lupin Atlantis Holdings, S.A. Reduced dose oral pharmaceutical compositions of fenofibrate
WO2013077821A1 (en) * 2011-11-23 2013-05-30 Mahmut Bilgic Homogeneous biguanide composition
WO2014091318A1 (en) * 2012-12-11 2014-06-19 Lupin Atlantis Holdings, S.A. Reduced dose pharmaceutical compositions of fenofibrate
MA41202A (fr) * 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
CA2978885A1 (en) * 2015-03-06 2016-09-15 The University Of North Carolina At Chapel Hill Polymeric metformin and its use as a therapeutic agent and as a delivery vehicle
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
EP3606527A1 (en) 2017-04-03 2020-02-12 Coherus Biosciences, Inc. Ppar-gamma agonist for treatment of progressive supranuclear palsy
EP4188352A1 (en) * 2020-07-31 2023-06-07 KRKA, d.d., Novo mesto Pharmaceutical formulation of metformin having low content of dimethylamine
WO2023234935A1 (en) * 2022-05-31 2023-12-07 Venkor Corporation Bonded microparticulates preparation and applications thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3907792A (en) * 1969-01-31 1975-09-23 Andre Mieville Phenoxy-alkyl-carboxylic acid derivatives and the preparation thereof
US4250191A (en) * 1978-11-30 1981-02-10 Edwards K David Preventing renal failure
US4499289A (en) * 1982-12-03 1985-02-12 G. D. Searle & Co. Octahydronapthalenes
US4686237A (en) * 1984-07-24 1987-08-11 Sandoz Pharmaceuticals Corp. Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
NZ248813A (en) * 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
TW384224B (en) * 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5543133A (en) * 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
FR2774591B1 (fr) * 1998-02-12 2000-05-05 Lipha Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
AP1224A (en) * 1998-03-19 2003-11-14 Bristol Myers Squibb Co Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
US6531158B1 (en) * 2000-08-09 2003-03-11 Impax Laboratories, Inc. Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
EP1424070A1 (en) * 2002-11-28 2004-06-02 Fournier Laboratories Ireland Limited Combination of a PPAR alpha agonist and metformin for decreasing the serum triglycerides

Also Published As

Publication number Publication date
US20080020046A1 (en) 2008-01-24
AU2005205930B2 (en) 2007-09-20
PL1706102T3 (pl) 2012-01-31
EP1706102A1 (en) 2006-10-04
JP2007518773A (ja) 2007-07-12
CN100531722C (zh) 2009-08-26
EA200601215A1 (ru) 2007-02-27
IL176903A0 (en) 2006-12-10
ZA200605882B (en) 2009-03-25
CA2553967A1 (en) 2005-08-04
PT1706102E (pt) 2011-12-16
JP4740881B2 (ja) 2011-08-03
ATE521338T1 (de) 2011-09-15
ES2370948T3 (es) 2011-12-26
EP1706102B1 (en) 2011-08-24
DK1706102T3 (da) 2011-12-19
MA28353A1 (fr) 2006-12-01
US20110305733A1 (en) 2011-12-15
WO2005070396A1 (en) 2005-08-04
CN1909890A (zh) 2007-02-07
BRPI0507022A (pt) 2007-06-05
EP1559419A1 (en) 2005-08-03
TNSN06222A1 (en) 2007-12-03
EA009773B1 (ru) 2008-04-28
CY1111961T1 (el) 2015-11-04
SI1706102T1 (sl) 2011-12-30
AU2005205930A1 (en) 2005-08-04

Similar Documents

Publication Publication Date Title
NO20062792L (no) Farmasoytiske formuleringer omfattende metformin og et fibrat og fremgangsmater for oppnaelse derav
WO2006025979A3 (en) Modulators of nuclear receptors
SG162804A1 (en) Pyrazole based lxr modulators
SE0301010D0 (sv) Novel compounds
HK1113790A1 (en) Selurampanel
TW200738666A (en) Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors
SE0301373D0 (sv) Novel compounds
MY144482A (en) Biphenyl compounds useful as muscarinic receptor antagonists
SE0301009D0 (sv) Novel compounds
MEP45308A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
CY1112960T1 (el) Παραγωγα ουριας, μεθοδοι για την παρασκευη τους και χρησεις αυτων
TW200612892A (en) Novel compounds
HK1122494A1 (en) Pharmaceutical compositions containing sc(fv)2 sc(fv)2
IS7965A (is) Þíenópýrimidíndíón og notkun þeirra í breytingu ásjálfsnæmissjúkdómi
EP1925319A4 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING SC (FV) 2
TW200630336A (en) Novel compounds
BR0205767B1 (pt) Sais de sulfônio, composições curáveis por radiação, formulações líquidas, e, método para a preparação dos sais de sulfônio
TW200621690A (en) Novel compounds
MX2009006055A (es) Formas cristalinas del acido (3s)-3-[n-(n'-(2-terc-butilfenil)oxam il)alaninil]amino-5-(2',3',5',6'-tetrafluorofenoxi)-4-oxopentanoi co.
DK1730147T3 (da) Substituerede 1,4,8-triazaspiro[4.5]decan-2-on-forbindelser til behandling af fedme
CY1108880T1 (el) Παραγωγα καρβοξαμιδιου ως ανταγωνιστες μουσκαρινικου υποδοχεα
MY141233A (en) Enantiomers of selected fused heterocyclics and uses thereof
CY1114562T1 (el) Υψηλης καθαροτητας μεγαλης κλιμακας παρασκευη στανσοπορφινης
EA200701687A1 (ru) Гидрохлорид аморфного лерканидипина
MX2008001560A (es) Nuevos compuestos analogos de la camptotecina, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application